Table 2.
Inhibitory activity of CFZ combined with CDDP in lung cancer cell lines
| Cell line | Simultaneous | CDDP→CFZ | CDDP→CFZ | |||
|---|---|---|---|---|---|---|
| IC 50 (nM) | Synergy Value | IC 50 (nM) | Synergy Value | IC 50 (nM) | Synergy Value | |
| NSCLC | ||||||
| H520 | 14.5 | Ant. | 427.3 | Ant. + | 87.6 | Ant. + |
| A549 | <1 | NC | 206.2 | Ant. + | 72.3 | Ant. + |
| H1993 | 173.1 | Ant. + | 134.0 | Ant. + | 200.6 | Ant. + |
| H460 | 14.8 | Syn. | 258.3 | Ant. + | 25.1 | Syn. |
| H1299 | <1 | NC | <1 | NC | <1 | NC |
| SCLC | ||||||
| SHP77 | 72.8 | Syn. | 171.8 | Syn. | 21.7 | Syn. + |
| DMS114 | <1 | NC | <1 | NC | <1 | NC |
Cells were treated with equivalent doses of CFZ and CDDP either simultaneously, CDDP followed by CFZ, or CFZ followed by CDDP and evaluated 96 hours after initial treatment. IC50 values represent the concentration at which the drug combination inhibited cell growth by 50%. Synergy values were determined with Calcusyn software from the combination index (CI) method described by Chou and Talalay [31]. CI interpretation: <0.3 strong synergism (Syn. +), 0.3-0.9 synergism (Syn.), 1–3 antagonism (Ant.), >3 strong antagonism (Ant. +), or not calculated due to high cell death at lowest dose (NC).